ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · Lancet Infect Dis · 2026-03-24

Cluster-randomised trial in 68 clusters in Oromia, Ethiopia: enhanced trachoma control (double-dose azithromycin MDA plus fly control and hygiene measures) did not lower conjunctival C trachomatis prevalence in children at 3 years v standard SAFE (2.2% v 2.7%; p=0.99).

RCTn = 68 clusters
Last et al. Double-dose azithromycin mass drug administration, facial cleanliness, and fly control measures for trachoma control in Oromia, Ethiopia (Stronger SAFE): a cluster-randomised controlled trial
Women's health · Int J Gynaecol Obstet · 2026-01-13

Unplanned secondary analysis of the A-PLUS RCT (29,278 women in labour in 7 low- and middle-income countries): single oral azithromycin 2 g did not significantly reduce postpartum haemorrhage (1.4% vs 1.6% placebo; RR 0.88, 95% CI 0.73–1.07) or transfusion (0.5% vs 0.5%).

Secondary analysisn = 29,278
Sidze et al. Intrapartum oral azithromycin for maternal infection prophylaxis and the risk of postpartum hemorrhage: A secondary analysis of the A-PLUS trial
Women's health · BJOG · 2026-01-02

Secondary analysis of the A-PLUS RCT (29,236 patients in labour): azithromycin's reduction in maternal infection did not vary by time from dose to delivery (RR 0.71 for both 12 h or less and over 12 h); no neonatal infection benefit at any interval.

Secondary analysisn = 29,236
Boelig et al. Timing of Prophylactic Intrapartum Azithromycin Administration and Efficacy in Prevention of Maternal and Infant Infections: A Secondary Analysis of a Randomized Controlled Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.